Media stories about Ritter Pharmaceuticals (NASDAQ:RTTR) have been trending somewhat positive on Tuesday, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Ritter Pharmaceuticals earned a media sentiment score of 0.05 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 46.8131420808829 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Here are some of the news stories that may have impacted Accern Sentiment’s rankings:

RTTR has been the topic of several analyst reports. Zacks Investment Research raised shares of Ritter Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.75 price target on the stock in a report on Saturday, September 9th. Roth Capital set a $2.00 price target on shares of Ritter Pharmaceuticals and gave the company a “buy” rating in a report on Monday, October 23rd. Finally, HC Wainwright lowered their price target on shares of Ritter Pharmaceuticals from $7.00 to $1.50 and set a “buy” rating on the stock in a report on Monday, October 23rd. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $2.92.

Shares of Ritter Pharmaceuticals (NASDAQ RTTR) opened at $0.33 on Tuesday. The stock has a market cap of $16.97 and a price-to-earnings ratio of -0.28. Ritter Pharmaceuticals has a fifty-two week low of $0.28 and a fifty-two week high of $3.75.

Ritter Pharmaceuticals (NASDAQ:RTTR) last posted its earnings results on Tuesday, October 31st. The biotechnology company reported ($0.14) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.14). equities analysts anticipate that Ritter Pharmaceuticals will post -0.76 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Ritter Pharmaceuticals (RTTR) Earns Daily Coverage Optimism Score of 0.05” was originally posted by Watch List News and is owned by of Watch List News. If you are reading this report on another site, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this report can be viewed at https://www.watchlistnews.com/ritter-pharmaceuticals-rttr-earns-daily-coverage-optimism-score-of-0-05/1783381.html.

About Ritter Pharmaceuticals

Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.

Insider Buying and Selling by Quarter for Ritter Pharmaceuticals (NASDAQ:RTTR)

Receive News & Ratings for Ritter Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.